Pre-Conference Workshop Day
Tuesday 25th February 2025
8:00 am
Morning Check In & Light Refreshments
9:00 am
09:00 amWorkshop A
Creating the ‘Ideal’ Radiopharmaceutical: Considerations for the Drug Design Toolbox
Synopsis
Delve into a holistic overview of the art of novel radiopharmaceutical drug design. With cutting-edge progress expanding the tools used in novel radiopharmaceutical drug development there is a great number of options to optimize the chemistry of your molecule. From targeting moiety, linker, chelator and payload – what are the considerations when approaching drug design and does an ‘ideal’ radiopharmaceutical truly exist?
Join this interactive discussion-based session to explore questions on:
- Considering what is the best starting point when developing a drug: targeting strategy or payload led?
- Exploring isotope agnostic approaches
- Understanding disease biology to create the optimal strategy for drug design
- Exploring toxicities and how to avoid them in varying modalities
12:00 pm
Lunch & Networking
1:00 pm
01:00 pmWorkshop B
Pharmacokinetics, Dosimetry, & Imaging: Radiopharmaceuticals Show the Whole Picture
Synopsis
Traditional drug development has well established assays, tools and technologies for preclinical research, but specialized tools in evolving world of radiopharmaceuticals offer powerful advantages.
Delve into this workshop to explore:
- Preclinical Imaging for PK Evaluation: Discover how tools like PET and SPECT are utilized in preclinical models to quickly visualize and quantify radiopharmaceutical biodistribution, uptake, and clearance, and how to leverage this towards optimized dosimetry and efficacy
- Dosimetry-Powered Insight: Explore the cutting edge of dosimetry and dose prediction, including the fusion of imaging and PK data, considerations for different isotopes and targeting agents, and emerging methods for more streamlined dosimetry predictions
- Entering the Clinic: Learn about how imaging, dosimetry, and PK allow uniquely efficient Phase 1 study design for radiopharmaceuticals, accelerating early-stage development by creating rich datasets that visualize potential toxicities and allow for rational therapeutic dose selection